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INTRODUCTION
Excessive daytime sleepiness (EDS) is defined as the inability to stay awake and alert during major waking episodes of the day, resulting into unintended lapses into drowsiness or sleep [1] . EDS is now acknowledged to substantially impair quality of life and work productivity, imposing a significant public health burden [2] . It has been reported to be implicated in up to 50% of work-related accidents, approximately 16% of motor vehicle accidents and 25% of home-based accidents [3] . Though EDS has strongly been associated with a range of neurological and psychiatric diseases including Parkinson's disease (PD), epilepsy and schizophrenia [4] , its prevalence in the general population has been estimated to be as high as 18% [5] . Several risk factors have been found to contribute to EDS including obesity, depression and age [6] . Although EDS can commonly manifest secondary to nocturnal sleep abnormalities and poor sleep hygiene [7] , it is not simply the consequence of sleep deprivation/disruption, hence potentially driven by distinct mechanisms [8] .
Several brain regions, including the thalamus, hypothalamus, locus coeruleus and dorsal raphe are known to participate in the initiation and maintenance of alertness and sleep, though it remains to be ascertained the mechanisms underlying the development of EDS. The thalamus, specifically, has considerable nonphotic influence on sleep and circadian rhythmicity. The low-and high-frequency spindles generated by the GABAergic inhibitory reticular thalamic interneurons play an active role in inducing, maintaining and advancing non-rapid eye movement (NREM) sleep towards deeper stages [9] .
Several neurotransmitters have also been implicated in playing significant roles in sleep and alertness, including norepinephrine, hypocretin, serotonin, GABA, glutamate and histamine.
However, considerable evidence has emphasised the key role of the dopaminergic system in the sleep-wake regulation. Wisor, Nishino [10] demonstrated that mice with deletion of the M A N U S C R I P T
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6 dopamine transporter (DAT) gene have 20% more wakefulness compared to controls and are unable to respond to psychostimulant drugs such as modafinil or amphetamine, suggesting that DAT may regulate wakefulness. Nearly all PD patients endure sleep disturbances, strongly suggesting the involvement of a dopaminergic component in the development of EDS. Studies have identified varying levels of extracellular dopamine in the terminal regions of ventral tegmental area (VTA) dopaminergic neurons across the sleep-wake cycle, with elevated levels of dopamine during waking and REM sleep [11] .
The origin of the dopamine innervation in the thalamus is markedly diverse, including dopaminergic projections from the VTA, the hypothalamus, and lateral parabrachial nucleus (LPbN), highlighting the complex organisation of the thalamus in terms of DAT content, distribution, density and origin [12] . The thalamus is also innervated by wake-active dopaminergic neurons from the ventral periaqueductal gray (vPAG), which also project to integral components of the sleep-wake regulatory system such as the prefrontal cortex, the ventrolateral preoptic nucleus (VPLO), the hypothalamic orexin/hypocretin cells, the pontine laterodorsal tegmental nucleus cholinergic neurons and the basal forebrain cholinergic neurons [13] .
A strong correlation has been identified between DAT binding and daytime sleepiness in PD [14] , as well as a correlation between dopamine D 2 /D 3 receptor binding and sleep deprivation [15] . Studies have also demonstrated a loss of vPAG gray matter dopaminergic neurons in patients with Multiple Systems Atrophy (MSA) and dementia with Lewy bodies (DLB), potentially contributing to excessive daytime sleepiness [16] , as well as the dose of dopaminergic treatment predicting EDS in MSA [17] . Taken together, these results support the hypothesis that dopaminergic dysfunction may be associated with daytime sleepiness.
Here we hypothesised that thalamic presynaptic dopaminergic function would be altered in patients with EDS and we sought to investigate this by assessing [
123 I]FP-CIT single photon emission computed tomography (SPECT) data, which is a molecular imaging marker of dopamine transporter (DAT). We screened 189 people registered as healthy subjects in the PPMI database. We included healthy subjects older than 30 years, with no significant neurological dysfunction and no first-degree family member with PD. All participants had a Montreal Cognitive Assessment (MoCA) score greater than 26 and Geriatric Depression Scale (GDS) score less than 5.
MATERIALS AND METHODS
Standard Protocol Approvals, Registrations, and Patient Consents
EDS was defined according to the ESS. This widely used, validated, self-reported and selfcompleted instrument consists of 8 items, rating from 0: normal to 3: severe, with a maximum score of 24; a higher score corresponding to a higher degree of EDS [18] .
Consistent with other studies, an ESS score of 10 or higher was set as a cut-off for EDS.
We identified 21 people with an ESS score of 10 or greater (≥10), satisfying the criteria for subjective EDS [18] . Using propensity scores [21] , people with EDS were matched 1:1 for M A N U S C R I P T A C C E P T E D [20] . Global cognitive status was measured using MoCA [21] . The following cognitive assessments were also performed: Benton Judgement of Line Orientation (BJLO) [22] , Hopkin's Learning Verbal Test-revised (HVLT) [23] , Semantic Fluency Test (SFT) [24] and Symbol Digit Modalities Test (SDMT) [25] . Autonomic dysfunction was assessed with
Scale for Outcomes for Autonomic Function (SCOPA-AUT) [26] . Olfactory dysfunction was measured by the University of Pennsylvania Smell Identification Test (UPSIT)). All 42 subjects enrolled in this study were non-demented, non-depressed and had no other neurological or psychiatric comorbidities. projections in a window centred on 159 ±10% KeV. Raw SPECT data for all subjects was transferred back to the Institute for Neurodegenerative Disorders Core Imaging Lab for standardised reconstruction, attenuation correction and quantification. Briefly, reconstruction was carried out using an iterative OSEM algorithm implemented on a Hermes workstation and subsequent processing was performed using PMOD (PMOD Technologies). A Chang 0 attenuation correction was applied using a site-specific mu empirically determined by the anthropomorphic brain phantom acquired at each site. A standard Gaussian 3D 6.0mm filter was applied to each image volume, followed by normalisation to standard MNI space. All SPECT images were visually interpreted by two experienced, independent readers who were blinded to the subject's clinical diagnosis.
Region of Interest analysis
For this study, normalised SPECT images were loaded together with a single subject MRI template in Montreal Neurological Institute (MNI) space using Analyze 11.0 software (Mayo Foundation). [ 123 I]FP-CIT SBRs in the thalamus, striatum, substantia nigra, globus pallidus, raphe nuclei, and locus coeruleus was calculated using a region of interest (ROI) analysis, with the occipital cortex serving as the reference region. ROIs were manually delineated on the MRI template using Analyze 11.0, before being applied on the SPECT images. ROIs where then manually adjusted on the SPECT images to compensate for individual variations, without altering the size or shape of the template.
The thalamus, caudate, putamen, globus pallidus and substantia nigra, were manually delineated using a reliable, repeatable and robust technique [27] . The raphe complex was M A N U S C R I P T
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10 drawn according to the anatomical location of the rostral and caudal raphe nuclei, as depicted by Hornung [28] . Regional estimates of Specific Brain Regions were calculated as the ratio of the mean ROI binding divided by the occipital cortex. This measure approximates the nondisplaceable binding potential (BP ND ), when the radioligand is in equilibrium at the target site and has previously been reported with Ioflupane SPECT [29] .
Statistical methods
Statistical analysis and graph illustration were performed with SPSS (version 20 Chicago, Illinois, USA) and GraphPad Prism (version 6.0c), respectively. For all variables, variance homogeneity and Gaussianity was tested with Kolmogorov-Smirnov test. Parametric (t-test) and non-parametric (Mann-Whitney U) test were used for between-group comparisons, as appropriate. Categorical variables were compared using a χ2 test. Univariate and multivariate linear regression analyses were performed to assess the main effects of clinical and imaging variables between healthy subjects with and without EDS, controlling for age and gender.
Sensitivity analysis was performed to evaluate the effect of gender on clinical and imaging variables. All data are presented as mean ±SD, and the level α was set for all comparisons at P<0.05.
RESULTS
In this study, we performed a case-control study in 21 people with EDS versus 21 healthy subjects without EDS, comparing semi-quantified [ 123 I]FP-CIT SPECT, neurobehavioural, neuropsychological, cognitive and autonomic features amongst the groups. There were no significant differences in neuropsychiatric, autonomic and cognitive assessments between the group of healthy subjects with and without EDS (all P>0.10; Table 2 ). CIT uptake in raphe nucleus and locus coeruleus has shown to provide indirect measures of serotonergic (serotonin transporter) and noradrenergic (noradrenergic transporter) system, respectively [29, 30] . We found no significant differences in raphe nucleus and locus coeruleus [ 123 I]FP-CIT SBRs between healthy subjects with and without EDS (P>0.10; Table   3 ). We also explored the effect of gender on clinical and imaging variables within the whole cohort and found no significant differences in DAT uptake in any of the regions of interest, as well as clinical variables, between males and females.
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DISCUSSION
Our findings demonstrate increased thalamic DAT uptake in people with EDS, which further correlates with the severity of EDS, suggesting that increased dopaminergic function may be associated with EDS in humans. By using non-invasive SPECT molecular imaging we found no other changes related to DAT in DAT-rich areas such as the striatum, substantia nigra or globus pallidus. [ 123 I]FP-CIT SPECT of raphe nucleus and locus coeruleus provides indirect measures for the serotonin and noradrenergic transporters, respectively [31] , however no uptake differences were found between people with EDS and healthy subjects without EDS.
Moreover, no other associations were found between imaging and clinical data related to M A N U S C R I P T
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14 neuropsychiatric, cognitive and autonomic function, suggesting that thalamic dopaminergic function may contribute to EDS development in humans.
There is growing evidence that dopamine modulates wakefulness, exerting a wake-promoting action. Studies have demonstrated that drugs that enhance dopaminergic signalling, through DAT blockade or inducing dopamine release, increase wakefulness in humans [32] . In fact, antipsychotic drugs that block dopamine D 2 receptors induce sedation in humans [33] and reduce wakefulness in rats [34] . Volkow, Wang [15] 
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The cellular basis underlying sleep regulation is complex, with much remaining poorly understood. Though dopamine has been implicated in regulating the sleep-wake cycle, the underlying dopamine pathway responsible for this remains unknown. Gonzalez, MorenoDelgado [38] identified a potential mechanism for how dopamine can regulate the sleep/wake cycle via a circadian-controlled receptor heteromer. They described how the production of serotonin and melatonin by the pineal gland is modulated by a circadian-related heteromerization of adrenergic and dopaminergic D 4 receptors, through which dopamine inhibits adrenergic receptor signalling, blocking the synthesis of melatonin [38] .
Furthermore, dopamine-containing neurons primarily arising in the VTA and substantia nigra pars compacta are recognised to innervate areas involved in sleep/wake regulation including the serotonergic cells of the dorsal raphe nucleus and medial raphe nucleus, the orexinergic arousal system of the lateral hypothalamus, the noradrenergic cells of the locus coeruleus, the histaminergic neurons of the posterior hypothalamus and the cholinergic cells of the basal forebrain [39] .
DAT content of dopaminergic axons has been found to vary across the thalamus, suggesting that dopaminergic signalling is more temporally and spatially restricted in particular regions of the thalamus. Therefore, an overall increase in DAT binding may actually be an indication of alterations of dopamine in specific thalamic nuclei, potentially differing from those inducing arousal. It is important to consider that the subjective nature of the ESS means that it can often be misjudged as fatigue or lassitude, thus not only presenting a diagnostic challenge, but it also hinders the ability to determine the physiology of daytime sleepiness. Patients and clinicians often use other terms such as 'fatigue' or 'tiredness' interchangeably, thus leading to semantic confusion. However, despite some overlap, EDS and fatigue have different features [45] . It would, therefore, be both useful and informative if we had additional comparisons Johns [47] reported that the MSLT was the least accurate measure of daytime sleepiness compared to ESS and Maintenance of Wakefulness Test (MWT), with ESS posing as the most accurate assessment of EDS. Further, Goldbart and colleagues concluded that the MSLT was had a large number of false positive results [48] .
It is also imperative to recognise that EDS has a multifactorial aetiology. Although our cohort did not report any sleep-specific comorbidities and were matched for RBDQ scores, it does not exclude the possibility of these subjects experiencing an unreported underlying sleep disorder such as sleep apnoea or restless legs syndrome, as well as mood disorders or side effects of medication. Therefore, although increased DAT uptake in the thalamus appears to be associated with EDS, it may be causally associated with other potential sleep disorders, which are inevitably reported to cause daytime sleepiness. Furthermore, Koch and colleagues demonstrated gender-specific differences in DAT uptake within the thalamus. Specifically, females were reported to have 31% higher DAT uptake within the thalamus compared to males [49] . Although the EDS cohort only encompassed an additional two females compared to the cohort without EDS, we took this notion into consideration and explored the potential effect of gender on DAT uptake. We did not find an association between gender and DAT uptake in any of the regions of interest, as well as gender having no effect on the association between thalamic DAT uptake and daytime sleepiness.
Furthermore, the complexity of EDS means that neither the sleep-state nor wakefulness can solely be explained by the action of a single site, but is presumed to arise as a result of the intimate interplay between many regions and distributed systems, including the orexinergic M A N U S C R I P T A C C E P T E D being governed by a complex, multilevel neuronal system in the brain stem, thalamus, hypothalamus and basal forebrain [52] . A disruption in any of these regions could potentially cause EDS, which could vary from individual to individual. Additionally, we included subjects with a pathological increase of ESS score. Though the ESS is widely used and recommended for screening for EDS, the subjective nature of the instrument inevitably introduces bias according to the subject's motivation, fatigue or recall.
Understanding the pathophysiology of EDS, including determining which systems are involved in this specific phenomenon, will not only heighten our understanding of sleep, but will encourage the development of therapies, with reduced side-effects, to tackle this symptom in the general public, as well as multicentric diseases such as PD. A variety of sleep-waking agents, including modafinil and methylphenidate are recognised to induce wakefulness via the dopaminergic system. Therefore, increasing our knowledge surrounding the mechanisms underlying sleepiness will allow selectivity for these effects, as well as tailoring these treatments based on the patient's neurophysiological alterations. Dopaminergic function, specifically DAT, should be further investigated to confirm its role in regulating the sleep-wake cycle. 
